RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹2,844.00up ₹7.90 (0.28%)BSE ₹2,847.20
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,836.10.
28 Oct: open ₹2,854.00, high ₹2,862.60, low ₹2,800.00
52-week range of traded prices to 28 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,704 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 7.77
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,99740.5% delivered
RPG Life Sciences share news and announcements
677 announcements, routine notices left out, newest first. Page 2 of 14.
Apr 2026
6 Apr · Updates
Feb 2026
3 Feb · Legal
Exchange has sought clarification from RPG Life Sciences Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act. -2. 2013 or as per Indian Accounting Standard. The response of the Company is awaited.
Jan 2026
28 Jan · General Updates
27 Jan · General Updates
27 Jan · Results
27 Jan · Board meeting
20 Jan · Board meeting
Dec 2025
29 Dec
15 Dec · General Updates
15 Dec · Board meeting
Nov 2025
Oct 2025
21 Oct · Legal
The exchange asked on 21 Oct 2025
17 Oct · Business
17 Oct · Board meeting
14 Oct · Analysts
13 Oct · Analysts
Sep 2025
1 Sep · Analysts
Aug 2025
20 Aug · Updates
Jul 2025
25 Jul · Business
25 Jul · Results
18 Jul · Board meeting
Jun 2025
23 Jun · Meeting
3 Jun · Updates
May 2025
Apr 2025
29 Apr · General Updates
28 Apr · Business